Drug Trial Radar · NCT00356681
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
Last checked: Nov 19, 2026Latest source record: Oct 15, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
282
Actual
Start
Dec 2006
Primary completion
Feb 2009
Study completion Aug 2012
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Jul 26, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To determine if treatment with paclitaxel plus AMG 706 is superior to paclitaxel plus AMG 706 placebo in subjects with HER2 negative locally recurrent or metastatic breast cancer. Also to estimate differences between treatment with paclitaxel plus AMG 706 and paclitaxel plus bevacizumab.
Conditions
- Breast Neoplasms
- Breast Tumors
- Breast Cancer
- Locally Recurrent and Metastatic Breast Cancer
Interventions
AMG 706 placeboDrug
Blinded placebo
BevacizumabDrug
Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
AMG 706Drug
AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
PaclitaxelDrug
Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate, measured radiologically and assessed by an independent review committee.Time frame: Last patient enrolled + 16 weeks of treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.